Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 10,000 shares of Aduro Biotech stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $10.59, for a total value of $105,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) opened at 10.35 on Friday. The company’s market capitalization is $772.23 million. Aduro Biotech, Inc. has a 12-month low of $8.75 and a 12-month high of $15.52. The firm has a 50-day moving average price of $11.14 and a 200 day moving average price of $10.93.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $3.98 million. During the same quarter in the prior year, the business posted $0.03 earnings per share. The company’s revenue was down 84.9% compared to the same quarter last year. On average, equities research analysts predict that Aduro Biotech, Inc. will post ($1.35) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/insider-selling-aduro-biotech-inc-adro-evp-sells-105900-00-in-stock/1615285.html.

Several large investors have recently made changes to their positions in ADRO. Legal & General Group Plc increased its holdings in shares of Aduro Biotech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares during the period. Tudor Investment Corp ET AL increased its holdings in shares of Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,984 shares during the period. Parametric Portfolio Associates LLC increased its holdings in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 2,119 shares during the period. Voya Investment Management LLC increased its holdings in shares of Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares during the period. Finally, American International Group Inc. increased its holdings in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 1,447 shares during the period. Institutional investors and hedge funds own 35.05% of the company’s stock.

Several equities research analysts recently weighed in on the company. William Blair restated an “outperform” rating on shares of Aduro Biotech in a research report on Monday, October 2nd. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Aduro Biotech in a research report on Wednesday, September 27th. BidaskClub lowered Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research lowered Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.00.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.